On June 26, 2019, the Centers for Medicare & Medicaid Services (CMS) approved a Medicaid State Plan Amendment (SPA) to allow Louisiana to implement a modified subscription arrangement in which the state will pay Asegua Therapeutics a monthly rate to provide an unrestricted amount of Asegua’s direct-acting antiviral, the authorized generic of Epclusa®. The medication will be used to treat Medicaid and DOC populations. The SPA allows Louisiana to cap gross expenditures at a fixed amount for hepatitis C drugs, while providing the state with unlimited access to clinically necessary doses of these therapies for Medicaid beneficiaries . . .